EDAP TMS SA FOCL
EDAP TMS S.A. ("EDAP," the "Company," "we," "us," or "our") is a medical technology company focused on the development, manufacturing, marketing, and sale of non-invasive therapeutic ultrasound and energy-based medical devices.
Our legal name is EDAP TMS S.A., and our commercial name is Focal One®. We were founded in 1979 as a société anonyme organized under the laws of France for a duration of 60 years from the date of incorporation, unless extended by shareholder approval in accordance with French corporate law. We are headquartered in Vaulx-en-Velin, France and operate in the United States, Europe, Asia and the rest of the world. We are listed on The Nasdaq Global Market ("Nasdaq") under the symbol "EDAP."
Valuation FY2025 figures against the last close
Where the revenue comes from as reported in the latest 10-K
Revenue by geography
- United States
- Asia
- Other geographical areas
- France
| Region | FY2025 | FY2024 |
|---|---|---|
| United States | $28.5M | $19.7M |
| Asia | $19.6M | $20.6M |
| Other geographical areas | $17.8M | $16.9M |
| France | $4.6M | $12.2M |
As the company reported it, from the “TOTAL SALES - Sales by Geographical Area (Details)” note of its latest 10-K. Every figure here has been checked against the total revenue the same filing reported. Regions are the filer's own and are not mapped onto a standard list — one company's “Americas” and another's “United States” are different areas, and making them look comparable would mean making at least one of them wrong. Slices under 1% are folded into “Other”.
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $70.5M | $69.4M | — | — | — | — | — | — | — | — |
| Cost of revenue | $40.5M | $40.7M | — | — | — | — | — | — | — | — |
| Gross profit | $30.0M | $28.7M | — | — | — | — | — | — | — | — |
| R&D | $9.7M | $8.4M | — | — | — | — | — | — | — | — |
| SG&A | $17.7M | $15.2M | — | — | — | — | — | — | — | — |
| Total operating expenses | $54.7M | $51.0M | — | — | — | — | — | — | — | — |
| Operating income | -$24.7M | -$22.2M | — | — | — | — | — | — | — | — |
| Interest expense | $789.0K | $256.0K | — | — | — | — | — | — | — | — |
| Pre-tax income | -$28.8M | -$20.3M | — | — | — | — | — | — | — | — |
| Income tax | $438.0K | $313.0K | — | — | — | — | — | — | — | — |
| Net income | -$29.2M | -$20.6M | — | — | — | — | — | — | — | — |
| EPS, basic | -0.78 | -0.55 | — | — | — | — | — | — | — | — |
| EPS, diluted | -0.78 | -0.55 | — | — | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 37.4M | 37.3M | 37.0M | 34.4M | 32.4M | 29.1M | 29.6M | 29.0M | 29.0M | 29.4M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $20.5M | $31.0M | $48.0M | — | — | — | — | — | — | — |
| Short-term investments | $0 | — | — | — | — | — | — | — | — | — |
| Receivables | $21.3M | $19.3M | — | — | — | — | — | — | — | — |
| Inventory | $12.8M | $19.2M | — | — | — | — | — | — | — | — |
| Total current assets | $57.2M | $72.6M | — | — | — | — | — | — | — | — |
| Property, plant and equipment | $9.9M | $7.6M | — | — | — | — | — | — | — | — |
| Goodwill | $2.8M | $2.5M | — | — | — | — | — | — | — | — |
| Other intangibles | $1.8M | $1.1M | — | — | — | — | — | — | — | — |
| Total assets | $79.0M | $89.4M | — | — | — | — | — | — | — | — |
| Short-term debt | $2.1M | $2.5M | — | — | — | — | — | — | — | — |
| Total current liabilities | $37.1M | $39.3M | — | — | — | — | — | — | — | — |
| Long-term debt | $15.9M | $2.2M | — | — | — | — | — | — | — | — |
| Total liabilities | $59.6M | $46.9M | — | — | — | — | — | — | — | — |
| Retained earnings | -$128.6M | -$99.4M | — | — | — | — | — | — | — | — |
| Total equity | $19.4M | $42.5M | $62.9M | — | — | — | — | — | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$14.7M | — | — | — | — | — | — | — | — |
| Depreciation and amortisation | $3.4M | $2.8M | — | — | — | — | — | — | — | — |
| Investing cash flow | -$5.7M | -$4.5M | — | — | — | — | — | — | — | — |
| Financing cash flow | $8.6M | $5.0M | — | — | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-060700.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | $69.4M | $70.5M |
| Gross profit | — | — | — | — | — | — | — | — | $28.7M | $30.0M |
| Net income | — | — | — | — | — | — | — | — | -$20.6M | -$29.2M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $122.04B | 25.6x | 8.4% |
| LIVN | LivaNova PLC | $4.46B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $2.45B | 14.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.05B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.89B | — | 28.9% |
| CNMD | CONMED Corp | $1.48B | 32.6x | 5.2% |
| CBLL | Ceribell, Inc. | $1.04B | — | 36.1% |